156(top 1%)
PR articles
15.6K(top 1%)
PR citations
58(top 1%)
PR h-index
64(top 1%)
h-index
172
documents
19.0K
doc citations
3.3K
citing journals
100
times ranked

Publications

156 peer-reviewed articles • 16,246 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Minimum clinically important difference (MCID) of the personal impact of epilepsy scale (PIES)
Epilepsy and Behavior, 2022, 130, 108691
1.42Citations (PDF)
2Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study
Epilepsy and Behavior, 2022, 134, 108811
1.417Citations (PDF)
3Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs
Epilepsy and Behavior, 2020, 102, 106634
1.45Citations (PDF)
4Living safely with epilepsy: a key learning review
Epileptic Disorders, 2020, 22, 364-380
1.29Citations (PDF)
5Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results
Epilepsy and Behavior, 2020, 112, 107312
1.49Citations (PDF)
6Identification of seizure clusters using free text notes in an electronic seizure diary
Epilepsy and Behavior, 2020, 113, 107498
1.45Citations (PDF)
7Assessing the personal impact of epilepsy in a population-based cohort of Veterans
Epilepsy and Behavior, 2020, 106, 107047
1.413Citations (PDF)
8Computational analysis of Seizure Clusters in electronic diary free text notes (1226)
Neurology, 2020, 94,
0.70Citations (PDF)
9Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials
Epilepsy and Behavior, 2019, 92, 31-35
1.45Citations (PDF)
10Risk of Hospitalization in Patients With Uncontrolled Epilepsy Treated with a Long Versus Short Half-Life Adjunctive Antiepileptic Medication (P3.5-002)
Neurology, 2019, 92,
0.70Citations (PDF)
11Adherence with Extended-Release Oxcarbazepine (Oxtellar XR®) vs. Immediate-Release Oxcarbazepine: Analysis of Pooled Data from Four National Pharmacy Claims Databases (P6.293)
Neurology, 2018, 90,
0.71Citations (PDF)
12Predictors of Clinically Meaningful Improvements in Health-Related Quality of Life Among Adults With Partial-Onset Epilepsy: A Pooled Analysis From Two Eslicarbazepine Acetate Monotherapy Trials (P6.283)
Neurology, 2018, 90,
0.70Citations (PDF)
13Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate
Epilepsy and Behavior, 2017, 68, 203-207
1.416Citations (PDF)
14Treatment issues for children with epilepsy transitioning to adult care
Epilepsy and Behavior, 2017, 69, 153-160
1.442Citations (PDF)
15Antiepileptic drug class-related healthcare costs among pediatric patients initiating monotherapy treatment for partial-onset seizures (P3.228)
Neurology, 2017, 88,
0.70Citations (PDF)
16Relationship between Seizure Frequency Reduction and Health-Related Quality of Life in Conversion-to-Monotherapy and Adjunctive Therapy Trials of Eslicarbazepine Acetate (P3.229)
Neurology, 2017, 88,
0.70Citations (PDF)
17Eslicarbazepine Acetate Associated with Reduced Seizure Severity in Addition to Reduced Seizure Frequency (P2.031)
Neurology, 2016, 86,
0.70Citations (PDF)
18Patients Treated with Eslicarbazepine Acetate Monotherapy Show Quality of Life Improvement (P2.028)
Neurology, 2016, 86,
0.70Citations (PDF)
19Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate
Epilepsy and Behavior, 2015, 53, 149-153
1.48Citations (PDF)
20Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use
Epilepsy and Behavior, 2015, 44, 40-46
1.49Citations (PDF)
21Use of an online epilepsy diary to characterize repetitive seizures
Epilepsy and Behavior, 2015, 47, 66-71
1.484Citations (PDF)
22The Personal Impact of Epilepsy Scale (PIES)
Epilepsy and Behavior, 2015, 42, 140-146
1.455Citations (PDF)
23Is a separate monotherapy indication warranted for antiepileptic drugs?
Lancet Neurology, The, 2015, 14, 1229-1240
13.742Citations (PDF)
24Elucidating the transdiagnostic dimensional structure of trauma-related psychopathology: Findings from VA cooperative study 504 – risperidone treatment for military service related chronic post traumatic stress disorder
Journal of Affective Disorders, 2015, 172, 331-336
3.112Citations (PDF)
25A Comparison of Instruments to Measure Depressive Symptoms among Patients with Refractory Partial-Onset Seizures (P3.192)
Neurology, 2015, 84,
0.70Citations (PDF)
26Baseline Depressive Symptoms as Predictive of Seizure Frequency Reduction among Epilepsy Patients with Partial-Onset Seizures: A Pooled Analysis of Phase III Clinical Trials of Adjunctive Treatment with Eslicarbazepine Acetate (P3.193)
Neurology, 2015, 84,
0.70Citations (PDF)
27Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model
Current Medical Research and Opinion, 2014, 30, 2329-2341
1.449Citations (PDF)
28Determining minimally important change thresholds for the Seizure Severity Questionnaire (SSQ)
Epilepsy and Behavior, 2014, 31, 286-290
1.420Citations (PDF)
29Healthcare utilization and costs in adults with stable and uncontrolled epilepsy
Epilepsy and Behavior, 2014, 31, 356-362
1.4159Citations (PDF)
30Sensitivity testing of the Seizure Severity Questionnaire (SSQ)
Epilepsy and Behavior, 2014, 31, 281-285
1.416Citations (PDF)
31Happy Anniversary, Epilepsy & Behavior
Epilepsy and Behavior, 2014, 40, 66
1.40Citations (PDF)
32Healthcare utilization and costs in children with stable and uncontrolled epilepsy
Epilepsy and Behavior, 2014, 32, 135-141
1.484Citations (PDF)
33Impact of Seizure Frequency Reduction on Health-Related Quality of Life Among Clinical Trial Subjects with Refractory Partial-Onset Seizures: A Pooled Analysis of Phase III Clinical Trials of Eslicarbazepine Acetate (P6.180)
Neurology, 2014, 82,
0.71Citations (PDF)
34Utilisation of Free Valproic Acid Determinations
Clinical Pharmacokinetics, 2012, 9, 94-95
2.10Citations (PDF)
35Microelectronic Systems for Monitoring and Enhancing Patient Compliance With Medication Regimens
Drugs, 2012, 49, 321-327
8.568Citations (PDF)
36Enhancing Patient Compliance in the Elderly
Drugs and Aging, 2012, 12, 7-15
2.363Citations (PDF)
37Tolerability of antiepileptic drugs: Can we determine differences?
Epilepsy and Behavior, 2012, 23, 187-192
1.411Citations (PDF)
38Defining minimally important change in QOLIE-31 scores: Estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures
Epilepsy and Behavior, 2012, 23, 230-234
1.490Citations (PDF)
39Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD
JAMA - Journal of the American Medical Association, 2011, 306, 493
14.4210Citations (PDF)
40The evolution of antiepileptic drug development and regulation
Epileptic Disorders, 2010, 12, 3-15
1.266Citations (PDF)
41Abstract #8: Trial Methodology of a Randomized, Double-blind, Parallel-Group Study Evaluating the Clinical Effectiveness of Carisbamate, Topiramate, and Levetiracetam As Adjunctive Treatment of Partial Onset Seizures in Adults
Neurotherapeutics, 2010, 7, 330-331
3.90Citations (PDF)
42Cognition across the lifespan: Antiepileptic drugs, epilepsy, or both?
Epilepsy and Behavior, 2010, 17, 1-5
1.4120Citations (PDF)
43Methodological approach to the definition of “non-adherence”
Epilepsy and Behavior, 2009, 15, 264
1.42Citations (PDF)
44Linguistic Validation of the Japanese Version of the Quality of Life in Epilepsy Inventory (QOLIE-31-P)
Journal of the Japan Epilepsy Society, 2009, 27, 22-32
0.116Citations (PDF)
45Quantitative Assessment of Seizure Severity for Clinical Trials: A Review of Approaches to Seizure Components
Epilepsia, 2008, 42, 119-129
3.089Citations (PDF)
46Medication Compliance and Persistence: Terminology and Definitions
Value in Health, 2008, 11, 44-47
1.01,976Citations (PDF)
47Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills
Current Medical Research and Opinion, 2007, 23, 2193-2203
1.442Citations (PDF)
48Improved Adherence with Contingency Management
AIDS Patient Care and STDs, 2007, 21, 30-40
2.1186Citations (PDF)
49Women with epilepsy: Hormonal issues from menarche through menopause
Epilepsy and Behavior, 2007, 11, 160-178
1.438Citations (PDF)
50The impact of seizures and adverse effects on global health ratings
Epilepsy and Behavior, 2007, 11, 179-184
1.429Citations (PDF)
51Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis
Current Medical Research and Opinion, 2007, 23, 2369-2377
1.421Citations (PDF)
52New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials
Biological Psychiatry, 2007, 61, 1290-1295
3.845Citations (PDF)
53A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases
Value in Health, 2007, 10, 3-12
1.0578Citations (PDF)
54Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations
Value in Health, 2007, 10, 498-509
1.087Citations (PDF)
55Psychiatric safety of ketamine in psychopharmacology research
Psychopharmacology, 2007, 192, 253-260
1.8110Citations (PDF)
56Non-compliance: the Achilles' heel of anti-fracture efficacy
Osteoporosis International, 2007, 18, 711-719
2.7145Citations (PDF)
57A systematic review of persistence and compliance with bisphosphonates for osteoporosis
Osteoporosis International, 2007, 18, 1023-1031
2.7418Citations (PDF)
58Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies
Southern Medical Journal, 2007, 100, 1214-1218
0.428Citations (PDF)
59The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France
Clinical Therapeutics, 2006, 28, 1686-1694
1.9100Citations (PDF)
60Response to Compliance With Hypertension Therapy: Why Standards Are Needed
Hypertension, 2006, 48,
4.70Citations (PDF)
61Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
Current Medical Research and Opinion, 2005, 21, 1453-1460
1.4376Citations (PDF)
62Differentiating anxiety and depression symptoms in patients with partial epilepsy
Epilepsy and Behavior, 2005, 6, 563-569
1.464Citations (PDF)
63Different aspects of adherence to antihypertensive treatments
Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 317-333
1.05Citations (PDF)
64Compliance with Inhaled Insulin Treatment Using the AERx®iDMS Insulin Diabetes Management System
Diabetes Technology and Therapeutics, 2004, 6, 800-807
3.822Citations (PDF)
65A Systematic Review of Adherence With Medications for Diabetes
Diabetes Care, 2004, 27, 1218-1224
5.61,115Citations (PDF)
66Quality of life improvement with conversion to lamotrigine monotherapy
Epilepsy and Behavior, 2004, 5, 224-230
1.446Citations (PDF)
67The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy
Epilepsy and Behavior, 2004, 5, 337-342
1.4150Citations (PDF)
68Improved mood states with lamotrigine in patients with epilepsy
Epilepsy and Behavior, 2004, 5, 702-707
1.439Citations (PDF)
69Development of a growth hormone injection questionnaire for adolescents
Journal of Adolescent Health, 2004, 34, 27-29
1.68Citations (PDF)
70Electronic monitoring and counseling to improve medication adherence
Behaviour Research and Therapy, 2004, 42, 409-422
2.2122Citations (PDF)
71Title is missing!
Journal of Behavioral Medicine, 2003, 26, 349-360
1.352Citations (PDF)
72Tolerability of levetiracetam in elderly patients with CNS disorders
Epilepsy Research, 2003, 56, 135-145
1.358Citations (PDF)
73Medication Compliance Feedback and Monitoring in a Clinical Trial: Predictors and Outcomes
Value in Health, 2003, 6, 566-573
1.0193Citations (PDF)
74The Influence of Comorbid Depression on Seizure Severity
Epilepsia, 2003, 44, 1578-1584
3.0122Citations (PDF)
75Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL
Schizophrenia Research, 2003, 63, 137-149
1.6155Citations (PDF)
76The influence of comorbid depression on quality of life for people with epilepsy
Epilepsy and Behavior, 2003, 4, 515-521
1.4192Citations (PDF)
77Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam
Epilepsy and Behavior, 2003, 4, 118-123
1.4135Citations (PDF)
78A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials
Epilepsy and Behavior, 2003, 4, 124-132
1.4168Citations (PDF)
79Medicine partnerships
British Heart Journal, 2003, 89, 19ii-21
5.46Citations (PDF)
80The relationship between poor medication compliance and seizures
Epilepsy and Behavior, 2002, 3, 338-342
1.4213Citations (PDF)
81Principles of Health-related Quality of Life: Assessment in Clinical Trials
Epilepsia, 2002, 43, 1084-1095
3.063Citations (PDF)
82Development of a new seizure severity questionnaire: initial reliability and validity testing
Epilepsy Research, 2002, 48, 187-197
1.386Citations (PDF)
83Psychometric Properties of the German Translation of the QOLIE-31
Epilepsy and Behavior, 2001, 2, 106-114
1.488Citations (PDF)
84Exploration of Changes in Health-Related Quality of Life after 3 Months of Vagus Nerve Stimulation
Epilepsy and Behavior, 2001, 2, 460-465
1.466Citations (PDF)
85A systematic review of the associations between dose regimens and medication compliance
Clinical Therapeutics, 2001, 23, 1296-1310
1.92,176Citations (PDF)
86Naltrexone in the Treatment of Alcohol Dependence
New England Journal of Medicine, 2001, 345, 1734-1739
26.4614Citations (PDF)
87Assessing the severity of seizures and epilepsy: which scales are valid?
Current Opinion in Neurology, 2001, 14, 225-229
2.424Citations (PDF)
88Refill Patterns of Atypical and Conventional Antipsychotic Medications at a National Retail Pharmacy Chain
Psychiatric Services, 2001, 52, 1248-1250
1.329Citations (PDF)
89Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation
Epilepsy Research, 2001, 47, 17-25
1.396Citations (PDF)
90Development and Validation of the Headache Needs Assessment (HANA) Survey
Headache, 2001, 41, 402-409
1.740Citations (PDF)
91The Short-Term Impact of Adjunctive Tiagabine on Health-Related Quality of Life
Epilepsia, 2001, 42, 70-75
3.013Citations (PDF)
92A systematic review of the safety profile of levetiracetam: a new antiepileptic drug
Epilepsy Research, 2001, 47, 77-90
1.3187Citations (PDF)
93Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia
Schizophrenia Bulletin, 2001, 27, 227-234
2.953Citations (PDF)
94Cue-dose training with monetary reinforcement
Journal of General Internal Medicine, 2000, 15, 841-847
1.5206Citations (PDF)
95Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam
Epilepsy Research, 2000, 41, 29-38
1.399Citations (PDF)
96Effect of Levetiracetam on Epilepsy-Related Quality of Life
Epilepsia, 2000, 41, 868-874
3.0126Citations (PDF)
97Quality of Life in Schizophrenia: A Comparison of Instruments
Schizophrenia Bulletin, 2000, 26, 659-666
2.9100Citations (PDF)
98Brief Report : Adolescents' Attitudes Toward Epilepsy : Further Validation of the Child Attitude Toward Illness Scale (CATIS)
Journal of Pediatric Psychology, 2000, 25, 339-345
1.364Citations (PDF)
99Development of the Quality of Life in Epilepsy Inventory for Adolescents: The QOLIE-AD-48
Epilepsia, 1999, 40, 1114-1121
3.0238Citations (PDF)
100Risk Factors for Poor Health-Related Quality of Life in Adolescents with Epilepsy
Epilepsia, 1999, 40, 1715-1720
3.0192Citations (PDF)
101New Antiepileptic Drugs: Comparison of Key Clinical Trials
Epilepsia, 1999, 40, 590-600
3.0191Citations (PDF)
102Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology
Clinical Neuropsychologist, 1999, 13, 157-170
1.46Citations (PDF)
103Practical issues in medication compliance
Transplantation Proceedings, 1999, 31, 7S-9S
0.520Citations (PDF)
104How Long to Wait for a Response to Clozapine: A Comparison of Time Course of Response to Clozapine and Conventional Antipsychotic Medication in Refractory Schizophrenia
Schizophrenia Bulletin, 1999, 25, 709-719
2.967Citations (PDF)
105Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
American Journal of Psychiatry, 1999, 156, 88-93
5.175Citations (PDF)
106Clozapine and Hospitalization
Psychiatric Services, 1999, 50, 114b-116
1.30Citations (PDF)
107Development and Cross‐Cultural Translations of a 31‐Item Quality of Life in Epilepsy Inventory
Epilepsia, 1998, 39, 81-88
3.0699Citations (PDF)
108REPLY
Epilepsia, 1998, 39, 233-233
3.09Citations (PDF)
109Complex partial and secondarily generalized seizure patients: cognitive functioning prior to treatment with antiepileptic medication
Epilepsy Research, 1998, 30, 1-9
1.366Citations (PDF)
110Seizure measurement in clinical trials
Journal of Epilepsy, 1998, 11, 256-260
0.69Citations (PDF)
111Predictors of differential response to clozapine and haloperidol
Biological Psychiatry, 1998, 44, 475-482
3.832Citations (PDF)
112Does Participation in Psychosocial Treatment Augment the Benefit of Clozapine?
Archives of General Psychiatry, 1998, 55, 618
12.768Citations (PDF)
113Achieving Long-Term Continuance of Menopausal ERT/HRT
Menopause, 1998, 5, 69???76
1.97Citations (PDF)
114A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
New England Journal of Medicine, 1997, 337, 809-815
26.4532Citations (PDF)
115Title is missing!
1997, 19, 227-230
10Citations (PDF)
116Compliance With Contraceptives and Other Treatments
Obstetrics and Gynecology, 1996, 88, 4S-12S
1.145Citations (PDF)
117A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis
Epilepsy Research, 1996, 25, 113-118
1.3192Citations (PDF)
118A Brief Questionnaire to Screen for Quality of Life in Epilepsy The QOLIE-10
Epilepsia, 1996, 37, 577-582
3.0362Citations (PDF)
119Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures
Neurology, 1996, 47, 68-76
0.7114Citations (PDF)
120Effect of Valproate on Cognitive Functioning
Archives of Neurology, 1996, 53, 1008
6.891Citations (PDF)
121Epilepsy-Reply
Archives of Neurology, 1996, 53, 476-477
6.80Citations (PDF)
122Development of the Quality of Life in Epilepsy Inventory
Epilepsia, 1995, 36, 1089-1104
3.0535Citations (PDF)
123Dose Frequency and Dose Interval Compliance with Multiple Antiepileptic Medications During a Controlled Clinical Trial
Epilepsia, 1995, 36, 1111-1117
3.0125Citations (PDF)
124Agreement between self reports and proxy reports of quality of life in epilepsy patients
Quality of Life Research, 1995, 4, 159-168
1.7135Citations (PDF)
125Relationship between medication compliance and medical outcomes
American Journal of Health-System Pharmacy, 1995, 52, S27-S29
0.650Citations (PDF)
126The Relationship of Neuropsychological Functioning to Quality of Life in Epilepsy
Archives of Neurology, 1995, 52, 997-1003
6.8310Citations (PDF)
127Quality of Life for People with Epilepsy
Neurologic Clinics, 1994, 12, 1-13
2.082Citations (PDF)
128Medication Compliance in Clinical Trials
Clinical Research and Regulatory Affairs, 1994, 11, 47-59
0.30Citations (PDF)
129Simultaneous HPLC Analysis of Carbamazepine and Carbamazepine Epoxide in Human Brain Microdialysate
Journal of Liquid Chromatography and Related Technologies, 1994, 17, 1567-1576
1.212Citations (PDF)
130A Pharmacodynamic Approach to the Estimate of Carbamazepine Autoinduction
Journal of Pharmaceutical Sciences, 1994, 83, 491-494
2.421Citations (PDF)
131Phenytoin concentrations in the human brain: An in vivo microdialysis study
Epilepsy Research, 1994, 18, 227-232
1.364Citations (PDF)
132Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis
Neurology, 1994, 44, 1469-1469
0.744Citations (PDF)
133A Clinimetric Approach to Assessing Quality of Life in Epilepsy
Epilepsia, 1993, 34,
3.069Citations (PDF)
134A Comparison of Valproate with Carbamazepine for the Treatment of Complex Partial Seizures and Secondarily Generalized Tonic–Clonic Seizures in Adults
New England Journal of Medicine, 1992, 327, 765-771
26.4707Citations (PDF)
135Reproductive Function in Epilepsy
Epilepsia, 1991, 32,
3.046Citations (PDF)
136Medication Compliance in Epilepsy
Archives of Internal Medicine, 1991, 151, 1236
8.110Citations (PDF)
137Comparison of a Noninstrumented Immunoassay for Carbamazepine to High Performance Liquid Chromatography and Fluorescence Polarization Immunoassay
Epilepsia, 1990, 31, 480-484
3.05Citations (PDF)
138Compliance Declines Between Clinic Visits
Archives of Internal Medicine, 1990, 150, 1509
8.1317Citations (PDF)
139Barbiturate-Related Connective Tissue Disorders
Archives of Internal Medicine, 1989, 149, 911
8.129Citations (PDF)
140How Often Is Medication Taken as Prescribed?
JAMA - Journal of the American Medical Association, 1989, 261, 3273
14.4748Citations (PDF)
141Improvement in cognitive functioning and mood state after conversion to valproate monotherapy
Neurology, 1989, 39, 1640
0.725Citations (PDF)
142Can categorization of patient background problems be used to determine early termination in a clinical trial?
Contemporary Clinical Trials, 1988, 9, 47-63
2.824Citations (PDF)
143Antiepleptic drug medication monitoring
Contemporary Clinical Trials, 1988, 9, 257
2.80Citations (PDF)
144Variable Free and Total Valproic Acid Concentrations in Sole- and Multi-Drug Therapy
Therapeutic Drug Monitoring, 1986, 8, 411-415
1.276Citations (PDF)
145Epilepsy, Sex Hormones, and Antiepileptic Drugs
Epilepsia, 1985, 26,
3.0144Citations (PDF)
146Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic Seizures
New England Journal of Medicine, 1985, 313, 145-151
26.41,143Citations (PDF)
147What happens to study dropouts?
Contemporary Clinical Trials, 1984, 5, 307
2.80Citations (PDF)
148Human Serum Teratogenicity Studied by Rat Embryo Culture: Epilepsy, Anticonvulsant Drugs, and Nutrition
Epilepsia, 1984, 25, 205-216
3.068Citations (PDF)
149Treatment of seizures with medroxyprogesterone acetate
Neurology, 1984, 34, 1255-1255
0.7196Citations (PDF)
150A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults
Neurology, 1983, 33, 14-25
0.734Citations (PDF)
151Historical perspective on the choice of antiepileptic drugs for the treatment of seizures in adults
Neurology, 1983, 33, 2-7
0.772Citations (PDF)
152A method of quantification for the evaluation of antiepileptic drug therapy
Neurology, 1983, 33, 26-37
0.7133Citations (PDF)
153Principles in designing clinical trials for antiepileptic drugs
Neurology, 1983, 33, 8-13
0.710Citations (PDF)
154Which patients will be lost to follow-up?
Contemporary Clinical Trials, 1981, 2, 78
2.82Citations (PDF)
155Central case validation
Contemporary Clinical Trials, 1980, 1, 169
2.81Citations (PDF)
156Valproic Acid
Therapeutic Drug Monitoring, 1979, 1, 105-116
1.285Citations (PDF)